Literature DB >> 25788677

Selective breeding for high anxiety introduces a synonymous SNP that increases neuropeptide S receptor activity.

David A Slattery1, Roshan R Naik2, Thomas Grund1, Yi-Chun Yen3, Simone B Sartori4, Andrea Füchsl1, Beate C Finger1, Betina Elfving5, Uwe Nordemann6, Remo Guerrini7, Girolamo Calo8, Gregers Wegener9, Aleksander A Mathé10, Nicolas Singewald4, Ludwig Czibere3, Rainer Landgraf3, Inga D Neumann11.   

Abstract

Neuropeptide S (NPS) has generated substantial interest due to its anxiolytic and fear-attenuating effects in rodents, while a corresponding receptor polymorphism associated with increased NPS receptor (NPSR1) surface expression and efficacy has been implicated in an increased risk of panic disorder in humans. To gain insight into this paradox, we examined the NPS system in rats and mice bred for high anxiety-related behavior (HAB) versus low anxiety-related behavior, and, thereafter, determined the effect of central NPS administration on anxiety- and fear-related behavior. The HAB phenotype was accompanied by lower basal NPS receptor (Npsr1) expression, which we could confirm via in vitro dual luciferase promoter assays. Assessment of shorter Npsr1 promoter constructs containing a sequence mutation that introduces a glucocorticoid receptor transcription factor binding site, confirmed via oligonucleotide pull-down assays, revealed increased HAB promoter activity-an effect that was prevented by dexamethasone. Analogous to the human NPSR1 risk isoform, functional analysis of a synonymous single nucleotide polymorphism in the coding region of HAB rodents revealed that it caused a higher cAMP response to NPS stimulation. Assessment of the behavioral consequence of these differences revealed that intracerebroventricular NPS reversed the hyperanxiety of HAB rodents as well as the impaired cued-fear extinction in HAB rats and the enhanced fear expression in HAB mice, respectively. These results suggest that alterations in the NPS system, conserved across rodents and humans, contribute to innate anxiety and fear, and that HAB rodents are particularly suited to resolve the apparent discrepancy between the preclinical and clinical findings to date.
Copyright © 2015 the authors 0270-6474/15/354599-15$15.00/0.

Entities:  

Keywords:  anxiety; basolateral amygdala; fear; paraventricular nucleus; promoter fragmentation

Mesh:

Substances:

Year:  2015        PMID: 25788677      PMCID: PMC6605130          DOI: 10.1523/JNEUROSCI.4764-13.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Authors:  Luca Cartegni; Shern L Chew; Adrian R Krainer
Journal:  Nat Rev Genet       Date:  2002-04       Impact factor: 53.242

3.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1.

Authors:  Luca Cartegni; Adrian R Krainer
Journal:  Nat Genet       Date:  2002-03-04       Impact factor: 38.330

4.  Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety.

Authors:  Simone A Krömer; Melanie S Kessler; Dale Milfay; Isabel N Birg; Mirjam Bunck; Ludwig Czibere; Markus Panhuysen; Benno Pütz; Jan M Deussing; Florian Holsboer; Rainer Landgraf; Christoph W Turck
Journal:  J Neurosci       Date:  2005-04-27       Impact factor: 6.167

5.  Inbred Roman high- and low-avoidance rats: differences in anxiety, novelty-seeking, and shuttlebox behaviors.

Authors:  R M Escorihuela; A Fernández-Teruel; L Gil; R Aguilar; A Tobeña; P Driscoll
Journal:  Physiol Behav       Date:  1999-08-01

6.  Comprehensive analysis of CpG islands in human chromosomes 21 and 22.

Authors:  Daiya Takai; Peter A Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

7.  Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects.

Authors:  Yan-Ling Xu; Rainer K Reinscheid; Salvador Huitron-Resendiz; Stewart D Clark; Zhiwei Wang; Steven H Lin; Fernando A Brucher; Joanne Zeng; Nga K Ly; Steven J Henriksen; Luis de Lecea; Olivier Civelli
Journal:  Neuron       Date:  2004-08-19       Impact factor: 17.173

8.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor.

Authors:  Jubao Duan; Mark S Wainwright; Josep M Comeron; Naruya Saitou; Alan R Sanders; Joel Gelernter; Pablo V Gejman
Journal:  Hum Mol Genet       Date:  2003-02-01       Impact factor: 6.150

9.  Chromatin-mediated restriction of nuclear factor 1/CTF binding in a repressed and hormone-activated promoter in vivo.

Authors:  Sergey Belikov; Carolina Astrand; Per-Henrik Holmqvist; Orjan Wrange
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

10.  The CpG island searcher: a new WWW resource.

Authors:  Daiya Takai; Peter A Jones
Journal:  In Silico Biol       Date:  2003
View more
  17 in total

1.  Identification of the first biased NPS receptor agonist that retains anxiolytic and memory promoting effects with reduced levels of locomotor stimulation.

Authors:  Stewart D Clark; Terrence P Kenakin; Steven Gertz; Carla Hassler; Elaine A Gay; Tiffany L Langston; Rainer K Reinscheid; Scott P Runyon
Journal:  Neuropharmacology       Date:  2017-03-03       Impact factor: 5.250

2.  Neuropeptide S Induces Acute Anxiolysis by Phospholipase C-Dependent Signaling within the Medial Amygdala.

Authors:  Thomas Grund; Inga D Neumann
Journal:  Neuropsychopharmacology       Date:  2017-08-14       Impact factor: 7.853

Review 3.  Bridging the Gap: Towards a cell-type specific understanding of neural circuits underlying fear behaviors.

Authors:  K M McCullough; F G Morrison; K J Ressler
Journal:  Neurobiol Learn Mem       Date:  2016-07-26       Impact factor: 2.877

Review 4.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

5.  Neuropeptide S Activates Paraventricular Oxytocin Neurons to Induce Anxiolysis.

Authors:  Thomas Grund; Stephanie Goyon; Yuting Li; Marina Eliava; Haikun Liu; Alexandre Charlet; Valery Grinevich; Inga D Neumann
Journal:  J Neurosci       Date:  2017-11-08       Impact factor: 6.167

Review 6.  Amygdala, neuropeptides, and chronic pain-related affective behaviors.

Authors:  Volker Neugebauer; Mariacristina Mazzitelli; Bryce Cragg; Guangchen Ji; Edita Navratilova; Frank Porreca
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

7.  Maternal Brain TNF-α Programs Innate Fear in the Offspring.

Authors:  Bojana Zupan; Bingfang Liu; Faten Taki; Judit Gal Toth; Miklos Toth
Journal:  Curr Biol       Date:  2017-11-30       Impact factor: 10.834

Review 8.  Pharmacology, Physiology and Genetics of the Neuropeptide S System.

Authors:  Rainer K Reinscheid; Chiara Ruzza
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-23

9.  Combined Neuropeptide S and D-Cycloserine Augmentation Prevents the Return of Fear in Extinction-Impaired Rodents: Advantage of Dual versus Single Drug Approaches.

Authors:  Simone B Sartori; Verena Maurer; Conor Murphy; Claudia Schmuckermair; Patrick Muigg; Inga D Neumann; Nigel Whittle; Nicolas Singewald
Journal:  Int J Neuropsychopharmacol       Date:  2016-06-01       Impact factor: 5.176

10.  A new bioinformatic insight into the associated proteins in psychiatric disorders.

Authors:  Wenlong Zhao; Wenjing Yang; Shuanglin Zheng; Qiong Hu; Ping Qiu; Xinghua Huang; Xiaoqian Hong; Fenghua Lan
Journal:  Springerplus       Date:  2016-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.